About this Calculator

The Gilenya (fingolimod) Dose Calculator is a clinical support tool for healthcare professionals. It determines the appropriate once-daily oral dose for patients aged 10 years and older with relapsing forms of multiple sclerosis (MS) based on key patient parameters: age, body weight, and hepatic function status.

This guide provides an overview of the calculator’s outputs, usage instructions, and essential clinical information related to fingolimod administration.

Outputs

After inputting the patient’s details, the calculator will provide one of the following outputs:

• Recommended Dose: Displays the calculated dose (0.5 mg or 0.25 mg) and the administration schedule (once daily).
• Dosing Rationale: Explains the basis for the recommendation, referencing the patient’s body weight.
• Hepatic Impairment Guidance: Provides specific information for patients with mild hepatic impairment (Child-Pugh Class A) and flags the contraindication for use in patients with moderate to severe impairment (Class B or C).
• Age-Related Restriction: Issues a notification if the entered age is below 10 years, as fingolimod is not approved for this population.

How to Use

To use the calculator, follow these steps:

1. Enter Patient Age: Input the patient’s age in years. The patient must be 10 years or older.
2. Enter Patient Weight: Input the patient’s body weight. You can use either kilograms (kg) or pounds (lbs).
3. Select Hepatic Status: Choose the patient’s hepatic impairment status from the dropdown menu, based on the Child-Pugh classification.
4. Calculate: Click the “Calculate Dose” button to view the recommendation. The output will appear below the input panel.

Dosing Overview

The recommended dosage of Gilenya is administered orally once daily, with or without food. The dose is determined by body weight for both adult and pediatric patients (age ≥10 years).

• Patients weighing > 40 kg (>88 lbs): The recommended dose is 0.5 mg orally once daily.
• Patients weighing ≤ 40 kg (≤88 lbs): The recommended dose is 0.25 mg orally once daily.

No dose adjustments are required for patients with mild hepatic impairment (Child-Pugh Class A), though use with caution is advised. Gilenya is contraindicated in patients with moderate (Class B) or severe (Class C) hepatic impairment.

Switching To Fingolimod

When switching from other disease-modifying therapies, consider their half-life and mechanism of action to avoid additive immunosuppressive effects.

• From Interferon or Glatiramer Acetate: Gilenya can typically be started immediately after discontinuation.
• From Natalizumab: A washout period of 2-3 months is generally recommended to minimize the risk of additive immunosuppression and progressive multifocal leukoencephalopathy (PML).
• From Teriflunomide or Alemtuzumab: Due to the long half-life and prolonged immune effects, exercise caution and clinical judgment. An accelerated elimination procedure may be needed for teriflunomide.

Missed Dose

Management of a missed dose depends on the duration of the treatment interruption:

• Interruption of 1 day or more during the first 2 weeks of treatment: Reinitiation requires first-dose observation, just like at the start of therapy.
• Interruption of more than 7 days during weeks 3 and 4 of treatment: Reinitiation requires first-dose observation.
• Interruption of more than 14 days after the first month of treatment: Reinitiation requires first-dose observation.

If an interruption is shorter than the periods described above, the patient can resume treatment with the next scheduled dose.

Safety Alerts

Frequently Asked Questions (FAQ)

1. What dose does the calculator recommend for a 12-year-old patient weighing 35 kg?

The calculator will recommend a dose of 0.25 mg once daily, as the patient’s weight is less than or equal to the 40 kg threshold.

2. Why does the tool show an error for an 8-year-old patient?

Gilenya (fingolimod) is not approved by the FDA for use in pediatric patients younger than 10 years of age. The calculator reflects this by restricting calculations to this age group.

3. What happens if I select “Moderate (Child-Pugh Class B)” for hepatic impairment?

The calculator will display a contraindication warning. Fingolimod is contraindicated in patients with moderate or severe hepatic impairment due to a significant increase in drug exposure, which can heighten the risk of adverse events.

4. Is a dose adjustment needed for an adult patient weighing 120 kg?

No. For any patient weighing more than 40 kg, the standard recommended dose is 0.5 mg once daily. There is no upward dose adjustment for higher body weights.

5. Why is first-dose observation required?

Fingolimod can cause a temporary slowing of the heart rate (bradycardia) and may delay atrioventricular conduction when treatment is started. First-dose observation, including ECG and vital sign monitoring, is a critical safety measure to manage these potential cardiac effects.

6. Does the dose need to be adjusted for renal impairment?

No dose adjustment is required for patients with renal impairment. The pharmacokinetics of fingolimod are not significantly altered in this population.

7. What pre-treatment screening is necessary before starting Gilenya?

Before initiation, patients require a recent (within 6 months) complete blood count (CBC), liver function tests, an electrocardiogram (ECG), varicella-zoster virus (VZV) antibody testing (if immunity is unknown), and a baseline ophthalmologic examination.

8. Can a patient switch from Gilenya to another MS therapy?

Yes, but because fingolimod remains in the blood for up to two months after discontinuation, caution is needed. Initiating other therapies during this period without a washout could lead to additive immunosuppressive effects and an increased risk of infection.

References

1. GILENYA® (fingolimod) capsules, for oral use. Prescribing Information. Novartis Pharmaceuticals Corporation. East Hanover, NJ. Updated Oct 2023. Accessed via FDA.gov.
2. Gilenya® HCP Official Website. Novartis. Accessed at hcp.gilenya.com.
3. U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Gilenya (fingolimod). Accessed at accessdata.fda.gov.
4. Kappos L, Radue EW, O’Connor P, et al; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0909494. Available at PubMed.